Overview
- Sanofi’s board decided on Feb. 11 not to renew Paul Hudson’s mandate, with his last day set for Feb. 17.
- Olivier Charmeil, executive vice president for General Medicines, will serve as interim chief executive during the transition.
- Belén Garijo is slated to assume duties after the April 29 annual meeting, when shareholders will also vote on her directorship and a change to raise the CEO age limit.
- Sanofi shares fell by roughly 3% to 4.5% following the announcement, and analysts offered mixed assessments of Garijo’s record at Merck KGaA.
- The leadership reset follows underwhelming trial updates and regulatory setbacks as Sanofi works to build growth before key Dupixent patents expire in the early 2030s.